Clinical Trials Logo

Clinical Trial Summary

Hyrimoz™ was developed as a biosimilar to HumiraTM (INN: adalimumab) and Zessly™ was developed as a biosimilar to RemicadeTM (INN: infliximab). Within the Biosimilar Development Program of Hyrimoz™ and Zessly™, two clinical confirmatory efficacy and safety studies were conducted: Hyrimoz™ in plaque psoriasis and Zessly™ in rheumatoid arthritis. Both confirmatory Phase III studies demonstrated equivalent efficacy and similar safety and immunogenicity of Hyrimoz™ to HumiraTM and Zessly™ to RemicadeTM, respectively.

The current study is designed to provide a systematic and consistent overview of the real-world data in biologic-naïve patients with moderate-to-severe Crohn's disease (CD). The data collected in this observational trial will be used to increase the knowledge of the effectiveness of Hyrimoz™ and Zessly™ in clinical routine care in patients with moderate-to-severe CD.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04022083
Study type Observational
Source Novartis
Contact Novartis Pharmaceuticals
Phone +41613241111
Email biopharma.clinicaltrials@sandoz.com
Status Recruiting
Phase
Start date June 24, 2019
Completion date June 30, 2025

See also
  Status Clinical Trial Phase
Completed NCT01860651 - Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease N/A
Completed NCT01102855 - Endomicroscopy and Crohn´s Disease N/A
Completed NCT01279577 - Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease Phase 2
Completed NCT01086553 - 9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease Phase 3
Completed NCT02763293 - Osteopathy Non-manipulative in Patients With Crohn's Disease. N/A
Completed NCT01289366 - Endocytoscopy for in Vivo Determination of Mucosal Inflammatory Cells and Intestinal Disease Activity in Inflammatory Bowel Disease (IBD) N/A
Recruiting NCT06006039 - The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Disease.
Completed NCT03890445 - Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
Completed NCT01564823 - Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease Phase 3
Completed NCT01768858 - Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
Completed NCT01417715 - Endomicroscopy for Assessment of Mucosal Healing
Completed NCT01417702 - Endoscopy for Assessment of Mucosal Healing in IBD
Terminated NCT00862121 - A Study With Pentasa in Patients With Active Crohn's Disease Phase 3